EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cooling immunochemotherapy and hematopoietic stem cell transplantation for refractory systemic epstein-barr virus-positive T-cell lymphoma in children: a single institution experience

Bo Kyung Kim, Kyung Taek Hong, Jung Yoon Choi, Hyun Jin Park, Hyoung Jin Kang

Annals of Hematology · 18.04.2026 · 105 (5)

DOI: 10.1007/s00277-026-06976-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 18.04.2026. Verfasst von Bo Kyung Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03722, Korea. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Infections, Antineoplastic Combined Chemotherapy Protocols, Lymphoma, T-Cell. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic Epstein-Barr virus-positive T-cell lymphoma (SEBVTL) of childhood is a rare and aggressive disorder often associated with hemophagocytic lymphohistiocytosis (HLH) and multiorgan failure. We reviewed six pediatric SEBVTL cases treated at Seoul National University Children’s Hospital between 2017 and 2024. All patients presented with HLH and bone marrow involvement. Initial management included the HLH-2004 protocol and chemotherapy. Since December 2022, cooling immunochemotherapy (etoposide and cytarabine) was introduced as a bridge to hematopoietic stem cell transplantation (HSCT). Median age at diagnosis was 8.2 years, and median follow-up was 8.5 months. Three patients treated before 2022 died of progressive disease. Among three patients managed with cooling immunochemotherapy and HSCT, two survived and one died of engraftment failure. The 1-year overall and event-free survival rates were both 33.3%. These findings suggest cooling immunochemotherapy followed by HSCT may improve outcomes in refractory pediatric SEBVTL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationEpstein-Barr Virus InfectionsAntineoplastic Combined Chemotherapy ProtocolsLymphoma, T-CellHerpesvirus 4, HumanImmunotherapyHumansFemaleChildMaleEtoposideChild, PreschoolCytarabineAdolescentCombined Modality TherapyLymphohistiocytosis, Hemophagocytic

Stichwörter der Autor:innen

Cooling immunochemotherapyEpstein-Barr virus-positive T-cell lymphomaHematopoietic stem cell transplantationHemophagocytic lymphohistiocytosis

Substanzen

EtoposideCytarabine

Autor:innen und Institutionen

  • Department of Pediatrics, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03722, Korea.
  • Seoul National University Cancer Research Institute, Seoul, Korea.
  • Department of Pediatrics, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03722, Korea. kanghj@snu.ac.kr.
  • Seoul National University Cancer Research Institute, Seoul, Korea. kanghj@snu.ac.kr.

Förderung

  • Seoul National University

Zitieren

APA

Kim, B. K., Hong, K. T., Choi, J. Y., Park, H. J., & Kang, H. J. (2026). Cooling immunochemotherapy and hematopoietic stem cell transplantation for refractory systemic epstein-barr virus-positive T-cell lymphoma in children: a single institution experience. Annals of Hematology, 105(5). https://doi.org/10.1007/s00277-026-06976-4

Vancouver

Kim BK, Hong KT, Choi JY, Park HJ, Kang HJ. Cooling immunochemotherapy and hematopoietic stem cell transplantation for refractory systemic epstein-barr virus-positive T-cell lymphoma in children: a single institution experience. Annals of Hematology. 2026;105(5). doi:10.1007/s00277-026-06976-4

BibTeX
@article{Kim2026,
  author = {Kim, Bo Kyung and Hong, Kyung Taek and Choi, Jung Yoon and Park, Hyun Jin and Kang, Hyoung Jin},
  title = {Cooling immunochemotherapy and hematopoietic stem cell transplantation for refractory systemic epstein-barr virus-positive T-cell lymphoma in children: a single institution experience},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {5},
  doi = {10.1007/s00277-026-06976-4}
}
Kostenlos starten →